Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$805.50 USD

805.50
2,196,548

-0.64 (-0.08%)

Updated Nov 5, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Stock Market News for Oct 14, 2020

Wall Street closed lower on Tuesday due to uncertainty on second round of coronavirus-aid package.

Lilly's Coronavirus Antibody Study Paused on Safety Concerns

Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.

Nalak Das headshot

5 Must-Buy Blue Chip Stocks to Remain Safe in October

It will be prudent to invest in Dow stocks with a favorable Zacks Rank that are likely to provide solid returns in the near term.

Gilead & Galapagos Announce Positive Data on UC Candidate

Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.

Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study

Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $154.49, marking a -1.52% move from the previous day.

AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage

AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.

The Zacks Analyst Blog Highlights: Mastercard, JPMorgan, Eli Lilly, Caterpillar and Anthem

The Zacks Analyst Blog Highlights: Mastercard, JPMorgan, Eli Lilly, Caterpillar and Anthem

Gilead Up on Positive Final Results for Coronavirus Treatment

Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.

Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study

Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs

Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.

Regeneron Gains on EUA Request for Coronavirus Treatment

Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.

Sheraz Mian headshot

Top Analyst Reports for Mastercard, JPMorgan & Eli Lilly

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), JPMorgan Chase (JPM) and Eli Lilly (LLY).

Company News for Oct 8, 2020

Companies in the news are: LLY, SUNW, SOL, KIN

Kinjel Shah headshot

Lilly Seeks Emergency Use of Coronavirus Antibody Candidate

Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.

David Bartosiak headshot

Best COVID Drug Stocks to Buy on Trump Recovery

Two of the best COVID drug stocks to buy became evident following President Trump's speedy recovery.

Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy

Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.

Sweta Killa headshot

4 Top ETFs, Stocks From Attractive Sectors Pre Q3 Earnings

We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.

Current Outlook Gloomy

Current Outlook Gloomy

Mark Vickery headshot

A Murky Way Forward, Plus Lilly's New Candidate

There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.

DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day

DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $146.63, marking a +0.98% move from the previous day.

Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive

The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.

Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance

The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.

Why Lilly (LLY) Could Beat Earnings Estimates Again

Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.